-
Mashup Score: 0Carotid Artery in Fanconi Anemia Following Transplant Assessed for Long-Term Cardiovascular Health I | Docwire News - 7 day(s) ago
A prospective study involved ultrasound imaging of patients’ carotid arteries to evaluate for structural changes.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1Preliminary Data Presented on Epoetin Alfa Dose Escalation With Stable Hydroxyurea for SCD Anemia | Docwire News - 10 day(s) ago
Preliminary efficacy and safety findings from a multicenter, open-label, phase Ib/II prospective study have been encouraging.
Source: docwirenews.comCategories: General Medicine News, Oncologists1Tweet-
An ongoing prospective study by @CmulNigeria, @PittTweet has promising initial efficacy, safety data for dose escalation of #epoetinalfa plus stable #hydroxyurea for tx of #anemia in #sicklecelldisease. #SCD, #ASH24, #Heme https://t.co/hfHRJfgfFO
-
-
Mashup Score: 0Liso-Cel in MZL, Follicular Lymphoma Produces Favorable Overall, Complete Response Rates | Docwire News - 12 day(s) ago
In the phase II TRANSCEND FL trial the CAR T-cell therapy has shown good efficacy and manageable safety in MZL and FL.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
From the #TRANSCENDFL phase II trial of #lisocabtagenemaraleucel: #Lisocel is showing favorable response rate performance in #marginalzonelymphoma, #follicularlymphoma, with manageable safety. #MZL, #Heme https://t.co/Wo0c5EFeWg
-
-
Mashup Score: 1New Lentiviral Vector–Transduced Hematopoietic Cell Therapy Shows Favorable Effect in Hemophilia A | Docwire News - 12 day(s) ago
A study cohort with severe disease over a median follow-up of 14 months had an annualized bleeding rate of zero.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
Progress in #genetherapy for severe #hemophilia A: In a study, autologous CD34-positive hematopoietic stem cells transduced with #CD68ET3LV #lentiviralvector had favorable effects in factor VIII expression, annualized bleeding rate. #Heme https://t.co/Y7viBC3up8
-
-
Mashup Score: 0In Vitro Diagnostic Test for B-Cell Lymphomas, Plasma Cell Neoplasms Receives FDA Clearance | Docwire News - 13 day(s) ago
Clinicians can use this test to help distinguish more than 60 disease subtypes from patients’ normal immune response.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
A way to improved speed, certainty of #Bcelllymphoma, #plasmacellneoplasm dx? @US_FDA grants clearance to a single-slide, in vitro #insituhybridization assay able to distinguish more than 60 subtypes of these diseases. #BCL, #Heme https://t.co/ImIm5iIdn1
-
-
Mashup Score: 2Kenneth Adler, MD, Reveals Drivers of Physician Burnout in Hematology, Explores Remedies | Docwire News - 14 day(s) ago
Organization-level changes at hospitals and medical groups are needed to meaningfully address this longstanding issue.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
Kenneth Adler, MD, of Morristown Medical Center in NJ, @ASH_hematology Committee on Practice, spoke with #Heme Today about the causes of physician #burnout in hematology, the institutional initiatives needed to meaningfully address it. #COVID19 https://t.co/INwcQCL4iI
-
-
Mashup Score: 1Clinical Trial of Water-Free Orally Dissolving Anticoagulant Successfully Concludes | Docwire News - 15 day(s) ago
The new agent is on the 505(b)(2) regulatory pathway and was compared with tablet-form apixaban in 60 healthy volunteers.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
#TAH3311, a new water-free dissolving film oral anticoagulant on the #505b2 regulatory pathway, has successfully concluded its clinical trial comparing it with tablet-form #apixaban. #Heme https://t.co/E90UUwsdPg
-
-
Mashup Score: 0Phase II Results Advance NPM1-Mutant AML Ziftomenib Monotherapy, Preparation for Combination Trials | Docwire News - 16 day(s) ago
The menin inhibitor oral agent achieved the KOMET-001 trial’s primary endpoints and had a favorable benefit-risk profile.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
Phase II #KOMET001 trial results: #Ziftomenib, an oral #menininhibitor designated a breakthrough therapy in NPM1-mutated #acutemyeloidleukemia by @US_FDA, achieved the trial primary endpoints for CR with a favorable benefit-risk profile. #AML, #Heme https://t.co/TEEkn8sSls
-
-
Mashup Score: 1Michael DeBaun, MD, MPH, on Communicating the Meaning of Sickle Cell Trait for Patient Outcomes | Docwire News - 17 day(s) ago
An expert panel’s review finds SCT has often been misattributed as the direct cause of mortality in patients who have SCT.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
Speaking with #Heme Today is Michael DeBaun, MD, MPH, of @VUMChealth who led an @ASH_hematology expert literature review assessing the clinical accuracy of directly attributing pt mortality to #sicklecelltrait. #sicklecelldisease, #SCD, #SCT https://t.co/RjnfGEDaVr
-
-
Mashup Score: 1New Lentiviral Vector–Transduced Hematopoietic Cell Therapy Shows Favorable Effect in Hemophilia A | Docwire News - 19 day(s) ago
A study cohort with severe disease over a median follow-up of 14 months had an annualized bleeding rate of zero.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
Progress in #genetherapy for severe #hemophilia A: In a study, autologous CD34-positive hematopoietic stem cells transduced with #CD68ET3LV #lentiviralvector had favorable effects in factor VIII expression, annualized bleeding rate. #Heme https://t.co/Y7viBC3up8
-
In a prospective study of pts with #Fanconianemia who underwent HSCT, researchers from @UMNews performed ultrasound imaging of the carotid artery for structural clues on pts' long-term cardiovascular health. #Heme, #Tandem24 https://t.co/NyktVl4s9v